Prof. Dr. med. Ulrich Keilholz

University Education

• 1977 - 1983 Medizinstudium Universitäten Mainz, Heidelberg, Lexington/USA
• 1983 - 1990 Wissenschaftlicher Assistent, Universität Heidelberg, Medizinische Klinik Heidelberg
• 1984 Promotion, Institut für Pathophysiologie und Sportmedizin, Universität Heidelberg

Professional Experience (selection)

• 2003 - 2006 International Society for Biological Therapy of Cancer (iSBTc), Vizepräsident 2003 - 2005, Präsident 2005 - 2006
• 2006 - 2009 European Society for Medical Oncology (ESMO) National Representative for Germany
• 2013 - 2018 Kommissarischer Direktor des Charité Comprehensive Cancer Center, Berlin
• 2015 Berufung zum Professor für Comprehensive Oncology (W3) und Vorsitzenden des Charité Comprehensive Cancer Center
• 2018 Direktor des Charité Comprehensive Cancer Center

Selected References

• Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., Peschel, C., Schadendorf, D., Garbe, C., O'Day, S., Daud, A., White, J. M., Xia, C., Patel, K., Kirkwood, J. M., & Keilholz, U. (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(17), 2823–2830.
• Eggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Salès, F., Gore, M., Mackie, R., Kusic, Z., Dummer, R., Hauschild, A., Musat, E., Spatz, A., Keilholz, U., & EORTC Melanoma Group (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (London, England), 372(9633). 117–126.
• Garbe, C., Eigentler, T. K., Keilholz, U., Hauschild, A., & Kirkwood, J. M. (2011). Systematic review of medical treatment in melanoma: current status and future prospects. The oncologist, 16(1), 5–24.
• Pallarz, S., Benary, M., Lamping, M., Rieke, D., Starlinger, J., Sers, C., Wiegandt, D. L., Seibert, M., Ševa, J., Schäfer, R., Keilholz, U., & Leser, U. (2019). Comparative Analysis of Public Knowledge Bases for Precision Oncology. JCO precision oncology, 3, PO.18.00371.
• Khoja, L., Atenafu, E. G., Suciu, S., Leyvraz, S., Sato, T., Marshall, E., Keilholz, U., Zimmer, L., Patel, S. P., Piperno-Neumann, S., Piulats, J., Kivelä, T. T., Pfoehler, C., Bhatia, S., Huppert, P., Van Iersel, L., De Vries, I., Penel, N., Vogl, T., Cheng, T., … Joshua, A. M. (2019). Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Annals of oncology : official journal of the European Society for Medical Oncology, 30(8), 1370–1380.
• Schütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., Worth, C. L., Schweiger, C., Liebs, S., Lange, M., Warnatz, H. J., Butcher, L. M., Barrett, J. E., Sultan, M., Wierling, C., Golob-Schwarzl, N., … Yaspo, M. L. (2017). Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nature communications, 8, 14262.
• Dietz, A., Wichmann, G., Kuhnt, T., Pfreundner, L., Hagen, R., Scheich, M., Kölbl, O., Hautmann, M. G., Strutz, J., Schreiber, F., Bockmühl, U., Schilling, V., Feyer, P., de Wit, M., Maschmeyer, G., Jungehülsing, M., Schroeder, U., Wollenberg, B., Sittel, C., Münter, M., … Keilholz, U. (2018). Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Annals of oncology : official journal of the European Society for Medical Oncology, 29(10), 2105–2114.
• Machiels, J. P., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Vermorken, J. B., Clement, P. M., Gauler, T., Cupissol, D., Grau, J. J., Guigay, J., Caponigro, F., de Castro, G., Jr, de Souza Viana, L., Keilholz, U., Del Campo, J. M., Cong, X. J., Ehrnrooth, E., Cohen, E. E., & LUX-H&N 1 investigators (2015). Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. The Lancet. Oncology, 16(5), 583–594.
• Chung, H. C., Arkenau, H. T., Lee, J., Rha, S. Y., Oh, D. Y., Wyrwicz, L., Kang, Y. K., Lee, K. W., Infante, J. R., Lee, S. S., Kemeny, M., Keilholz, U., Melichar, B., Mita, A., Plummer, R., Smith, D., Gelb, A. B., Xiong, H., Hong, J., Chand, V., … Safran, H. (2019). Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. Journal for immunotherapy of cancer, 7(1), 30.
• Verver, D., van Klaveren, D., van Akkooi, A., Rutkowski, P., Powell, B., Robert, C., Testori, A., van Leeuwen, B. L., van der Veldt, A., Keilholz, U., Eggermont, A., Verhoef, C., & Grünhagen, D. J. (2018). Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. European journal of cancer (Oxford, England : 1990), 96, 25–33.
• Mocellin, S., Keilholz, U., Rossi, C. R., & Nitti, D. (2006). Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends in molecular medicine, 12(3), 130–139.
• Garbe, C., Keim, U., Suciu, S., Amaral, T., Eigentler, T. K., Gesierich, A., Hauschild, A., Heinzerling, L., Kiecker, F., Schadendorf, D., Stadler, R., Sunderkötter, C., Tüting, T., Utikal, J., Wollina, U., Zouboulis, C. C., Keilholz, U., Testori, A., Martus, P., Leiter, U., … German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer (2020). Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(22), 2543–2551.
• Sinn, M., Sinn, B. V., Treue, D., Keilholz, U., Damm, F., Schmuck, R., Lohneis, P., Klauschen, F., Striefler, J. K., Bahra, M., Bläker, H., Bischoff, S., Pelzer, U., Oettle, H., Riess, H., Budczies, J., & Denkert, C. (2020). TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(14), 3732–3739.
• Gronbach, L., Wolff, C., Klinghammer, K., Stellmacher, J., Jurmeister, P., Alexiev, U., Schäfer-Korting, M., Tinhofer, I., Keilholz, U., & Zoschke, C. (2020). A multilayered epithelial mucosa model of head neck squamous cell carcinoma for analysis of tumor-microenvironment interactions and drug development. Biomaterials, 258, 120277.
• Keilholz, U., Mehnert, J. M., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L., Lee, K. W., Kasturi, V., Chin, K., von Heydebreck, A., & Gulley, J. L. (2019). Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. Journal for immunotherapy of cancer, 7(1), 12.